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Memory CD8+ T  cells are ideal candidates for cancer immunotherapy because they 
can mediate long-term protection against tumors. However, the therapeutic potential of 
different in vitro-generated CD8+ T cell effector subsets to persist and become memory 
cells has not been fully characterized. Type 1 CD8+ T (Tc1) cells produce interferon-γ and 
are endowed with high cytotoxic capacity, whereas IL-17-producing CD8+ T (Tc17) cells 
are less cytotoxic but display enhanced self-renewal capacity. We sought to evaluate 
the functional properties of in vitro-generated Tc17 cells and elucidate their potential to 
become long lasting memory cells. Our results show that in vitro-generated Tc17 cells 
display a greater in vivo persistence and expansion in response to secondary antigen 
stimulation compared to Tc1 cells. When transferred into recipient mice, Tc17 cells persist 
in secondary lymphoid organs, present a recirculation behavior consistent with central 
memory T cells, and can shift to a Tc1 phenotype. Accordingly, Tc17 cells are endowed 
with a higher mitochondrial spare respiratory capacity than Tc1 cells and express higher 
levels of memory-related molecules than Tc1 cells. Together, these results demonstrate 
that in  vitro-generated Tc17 cells acquire a central memory program and provide a 
lasting reservoir of Tc1 cells in vivo, thus supporting the use of Tc17 lymphocytes in the 
design of novel and more effective therapies.
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inTrODUcTiOn
Effector CD8+ T cells can be classified into at least two functional subsets. Type 1 CD8+ T (Tc1) 
cells produce interferon (IFN)-γ and are endowed with high cytotoxic capacity. Type 17 CD8+ 
T (Tc17) cells produce IL-17 and display enhanced self-renewal potential. The presence of Tc17 
cells has been described in several infectious and autoimmune diseases in both human and mice 
(1, 2), thus confirming the role of Tc17 cells in inflammatory processes. The accumulation of 
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Tc17 lymphocytes has also been observed in several types of 
human tumors including gastric (3), uterus (4), head and neck 
(5), liver (6), and colon cancer (7) and also in various cancer 
models such as B16 melanoma (8). In spite of their relatively 
low abundance in several tumors, we and others have reported 
that the adoptive transfer of in  vitro-generated Tc17 cells 
promotes the elimination of established tumors in C57BL/6 
mice, supporting evidence of antitumor properties of Tc17 
lymphocytes (9–12).
The fact that in  vitro-generated Tc17 lymphocytes do not 
express cytotoxic molecules such as granzymes and perforins (13) 
and thus are not able to induce apoptosis of target cells (14) opens 
questions regarding the mechanisms that could explain the anti-
tumor potential of Tc17 lymphocytes in vivo. In search of evidence 
which may account for this dichotomy, we demonstrated that 
Tc17 cells are highly plastic and some cells differentiate into Tc1 
IFN-γ+/granzyme B+ cells upon transfer into tumor-bearing mice 
(12). Moreover, Restifo and collaborators further suggested that 
the effectiveness of Tc17 lymphocyte adoptive therapy depends 
on the ability of these cells to differentiate into IFN-γ-producing 
cells (9). Accordingly, Dutton’s group reported that after adoptive 
transfer, Tc17 cells promote the recruitment of macrophages and 
neutrophils to the tumor microenvironment through the produc-
tion of IFN-γ, TNF-α, and IL-17 (10).
Recently, it has been suggested that Tc17 cells may display 
phenotypic features of memory T cells. The group of Takiguchi 
described that human Tc17 cells are found within the CD28+ 
CD45RA− memory subset in healthy donors (15). Also, other 
reports have shown that both endogenous and in vitro-generated 
Tc17 cells express high levels of the TCF-7 transcription factor 
(16, 17), suggesting an active Wnt/β-catenin signaling, which 
constitutes a major pathway in maintaining the molecular 
program of memory T lymphocytes. In the context of cancer, it 
has been reported that adoptively transferred Tc17 lymphocytes 
have greater persistence in  vivo compared to Tc1 lymphocytes 
(9) and that Tc17 lymphocytes exhibit high IL-7 receptor 
alpha chain (CD127) expression (11), which may explain their 
increased survival capacity. Finally, it has been shown that Tc17 
cells can differentiate into tissue-resident memory T  cells after 
the resolution of psoriasis (18). However, it is unclear whether 
Tc17 lymphocytes possess other functional features of memory 
cells, such as the ability to mount a secondary response and an 
OXPHOS-based metabolism.
Based on these previous findings, we sought to evaluate 
whether Tc17 cells present functional properties of memory 
CD8+ T cells. For this, we generated OVA-specific Tc17 cells and 
transferred the cells into wild-type mice to test their capacity to 
expand upon a secondary challenge. We show that Tc17 cells per-
sist in the long term, expand upon a secondary stimulation with 
OVA, shift to a Tc1 phenotype and recirculate within secondary 
lymphoid organs. In agreement, Tc17 cells are endowed with a 
higher mitochondrial spare respiratory capacity (SRC) compared 
to conventional (Tc1) cytotoxic CD8+ T cells. Finally, Tc17 cells 
express higher levels of memory-related markers and lower levels 
of molecules required for the effector program compared to Tc1 
cells. Together, these results suggest that Tc17 cells present func-
tional properties of central memory CD8+ T cells.
MaTerials anD MeThODs
Mice
C57BL/6 (CD45.2+), B6SJL-PTPRC (CD45.1+), OT-I, and 
Rag1−/− mice were purchased from The Jackson Laboratory. All 
mice were kept in the animal facility at Fundación Ciencia y 
Vida and maintained according to the “Guide to Care and Use 
of Experimental Animals, Canadian Council on Animal Care.” 
Animal work was carried out under institutional regulations of 
Fundacion Ciencia & Vida and Facultad de Ciencias, Universidad 
de Chile and was approved by the local ethics review committees.
generation of Tc17 and Tc1 cells
Naive CD8+ T cells were purified from spleens and lymph nodes of 
OT-I mice. Briefly, the spleen was perfused with RPMI 1640 sup-
plemented with 10% FCS, and CD8+ T cells were negatively selected 
using MACS (Miltenyi Biotec) following the manufacturer’s 
instructions. Following enrichment of CD8+ T cells, naive CD8+ 
T  cells (CD8+/CD44lo/CD62Lhi/CD25−) were obtained by cell 
sorting (FACS Aria III, BDBiosciences). Naive CD8+ T cells were 
cultured in a 96-well round bottom microplate (105 CD8+ T cells/
well) and were activated with soluble α-CD3 (1 µg/ml; clone 145-
2C11, eBioscience) and α-CD28 (1 µg/ml; clone 37.51) for 4 days 
in the presence of different cytokine cocktails. To generate Tc17 
cells, CD8+ T cells were differentiated for 4 days in the presence 
of 2 ng/ml recombinant human TGF-β1 (eBioscience), 20 ng/ml 
recombinant mouse IL-6 (eBioscience), and 5  µg/ml of anti-
IFN-γ (clone XMG1.2, Biolegend). Tc1 cells were differentiated 
for 4 days in the presence of 10 ng/ml recombinant mouse IL-2 
(eBioscience) using a protocol modified from the literature which 
replicates the clinical protocol of expanding human tumor infil-
trating lymphocytes (13). Cells were then harvested for in vitro 
experiments, adoptive transfer experiments, RNA extraction, 
intracellular cytokine staining, and flow cytometry.
intracellular staining and Flow cytometry
To assess cytokine production by adoptively transferred Tc1 
and Tc17 cells, cells obtained from lymph nodes, spleen, and 
peritoneal cavity of recepient mice were re-stimulated with 
0.25 µM PMA (Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-
Aldrich) in the presence of GolgiPlug (BD Biosciences) for 
4  h. Cells were stained with antibodies against the cell surface 
markers (congenic markers) and then resuspended in a fixation/
permeabilization solution (Cytofix/Cytoperm; BD Pharmingen). 
Following fixation and permeabilization, the cells were incubated 
with antibodies against IFN-γ, IL-2, IL-17, and TNF-α for 30 min 
at 4°C. The cells were then washed with permeabilization buffer 
and resuspended in PBS supplemented with 2% FCS for FACS 
analysis (FACSCanto II; BD Bioscience). In some cases, Fixable 
Viability Dye (eBioscience) was used to discard dead cells from 
the analysis.
Intracellular staining for Ki67 was conducted by incubating 
surface stained cells in a fixation/permeabilization solution 
(Foxp3/transcription factor permeabilization and fixation buffer, 
eBioscience). Following fixation and permeabilization, the cells 
were incubated with the Ki-67 antibody (clone 11F6, Biolegend) 
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in a permeabilization buffer (Foxp3/transcription factor permea-
bilization buffer, eBioscience). After staining, cells were washed 
and analyzed by FACS. FACS data analysis was performed using 
the FLOWJO software (Tree Star Inc., Ashland, OR, USA).
qPcr
Tc1 and Tc17 cells were differentiated in  vitro, and total RNA 
was extracted. Naive CD8+ T cells were isolated by cell sorting 
(CD8+/CD44lo/CD62Lhi/CD25−) before RNA extraction. Total 
RNA was obtained using EZNA Total RNA Kit I (Ω Bio-Tek). 
RNA (1  µg) was reverse-transcribed using M-MLV reverse 
transcriptase (Promega). The PCR reaction was performed using 
Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies) 
in a Stratagene Mx3000P real-time PCR machine. For relative 
quantitation, the amplified fragments were normalized according 
to constitutive transcription of the housekeeping gene HPRT. 
The sequences of the primers used for quantification of each 
measured transcript were the following:
tcf7 forward 5′- CAA TCT GCT CAT GCC CTA CC -3′, 
reverse 5′- CTT GCT TCT GGC TGA TGT CC -3′; lef1 forward 
5′- TGA GTG CAC GCT AAA GGA GA -3′, reverse 5′- CTG 
ACC AGC CTG GAT AAA GC -3′; bcl6 forward 5′- CTG CAG 
ATG GAG CAT GTT GT -3′, reverse 5′- CAC CCG GGA GTA 
TTT CTC AG -3′; klf2 forward 5′- TGT GAG AAA TGC CTT 
TGA GTT TAC TG -3′, reverse 5′- CCC TTA TAG AAA TAC 
AAT CGG TCA TAG TC-3′; tbx21 forward 5′- CCT GTT GTG 
GTC CAA GTT CA AC-3′, reverse 5′- CAC AAA CAT CCT GTA 
ATG GCT TGT -3′; eomes forward 5′- GCG CAT GTT TCC TTT 
CTT GAG -3′, reverse 5′- GGT CGG CCA GAA CCA CTT C -3′; 
prdm1 forward 5′- GAC GGG GGT ACT TCT GTT CA -3′, 
reverse 5′- GGC ATT CTT GGG AAC TGT GT -3′; grzb forward 
5′- ATC AAG GAT CAG CAG CCT GA-3′, reverse 5′- TGA TGT 
CAT TGG AGA ATG TCT -3′; pfn1 forward 5′- GAT GTG AAC 
CCT AGG CCA GA -3′, reverse 5′- TGA TGT CAT TGG AGA 
ATG TCT -3′; hprt forward 5′- CTC CTC AGA CCG CTT TTT 
GC -3′, reverse 5′- TAA CCT GGT TCA TCA TCG CTA ATC -3′.
Western Blot
Cell lysis was performed using Cytobuster protein extraction 
reagent (Novagen) supplemented with protease and phosphatase 
inhibitors (complete PhosSTOP, Roche). Protein extracts were 
separated in 15% SDS-polyacrylamide gels and transferred to 
PDVF membranes (Millipore). Blocking was at room tempera-
ture for 1 h in 5% fat-free milk, and membranes were incubated 
overnight at 4°C with 1:2,000 dilution of Total OXPHOS Human 
WB Antibody Cocktail (ab110411), and then for 1  h at room 
temperature with a secondary antibody conjugated to horserad-
ish peroxidase. Chemiluminescence detection used SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) 
and series of timed exposure images were acquired with a 
Chemidocs imaging system (BioRad) to ensure densitometric 
analyses were performed at exposures within the linear range. 
To ensure equal protein loading across gels, membranes were 
submerged in stripping buffer (Restore Western blot stripping 
buffer; Pierce), incubated at 37°C for 30 min, and re-probed with 
a loading control antibody. Image J was used for densitometric 
analysis.
adoptive Transfer of Tc1 and Tc17 cells
To assess secondary expansion of transferred cells, Tc1 and Tc17 
lymphocytes were generated in  vitro from OT-I/CD45.2+ and 
OT-I CD45.1+/CD45.2+ mice, respectively. On the day of the 
transfer, the Tc1 and Tc17 lymphocytes were counted and mixed 
at a 1:1 ratio. The initial ratio (input) on the cytometer was then 
evaluated by staining against CD45.1 and CD45.2. A total of 
2 ×  106 cells from this mixture were transferred intravenously 
into B6.SJL (CD45.1+) congenic mice. At day 23 post-adoptive 
transfer, the mice were immunized with 500 µg of OVA protein 
(Sigma-Aldrich) and 100 µl of Freund’s Complete Adjuvant (CFA, 
Sigma) intraperitoneally. On days 10, 20, and 27 post-adoptive 
transfer blood samples were obtained and analyzed by flow 
cytometry. Finally, on day 27 after the adoptive transfer, the mice 
were sacrificed, and cells obtained from the peritoneal cavity, 
secondary lymphoid organs, and spleen were analyzed by FACS.
To examine the ability of Tc17 cells to be retained in effec-
tor tissues, we performed intradermal injections of in  vitro- 
differentiated CD45.2+ Tc1 and CD45.1+/CD45.2+ Tc17 cells 
(1.5 × 106 cells per mice, at a 1:1 ratio) into CD45.1+ congenic 
mice, and 30 days later, we analyzed skin, secondary lymphoid 
organs, spleen, bone marrow, lung, and liver for the transferred 
cells. The intradermal transfer was performed by injecting 100 µl 
of cellular suspension in PBS divided in five spots of 20 µl each in 
the lower back skin of each mouse.
homeostatic survival
For in vitro homeostatic survival analysis, Tc1 and Tc17 cells were 
cultured in the presence of IL-15 (25 ng/ml, eBioscience) or IL-7 
(10  ng/ml, eBioscience). Three days later, cells were harvested, 
counted, and analyzed by FACS.
For in vivo homeostatic survival analysis, Tc1 and Tc17 lym-
phocytes were generated in  vitro from CD45.2+ and CD45.1+/
CD45.2+ mice, respectively, and co-transferred (0.5 × 106 cells of 
each type) in Rag1−/− mice. The transferred cells were evaluated 
10, 25, 75, and 115 days after in blood samples using counting 
beads (eBioscience).
homing assay
Tc1 and Tc17 lymphocytes were generated in vitro from CD45.2+ 
mice and stained with eFluor 670 (Thermofisher Scientific, 5 µM) 
and CMTMR (Thermofisher Scientific, 10  µM), respectively. 
Then, the cells were co-transferred (0.5 × 106 cells of each type) in 
CD45.1+ mice. Homing was evaluated 24 h later. Homing index in 
each organ was calculated as (Tc17organ/Tc1organ)/(Tc17input/Tc1input).
seahorse
Oxygen consumption rates (OCRs) and extracellular acidifica-
tion rates (ECARs) from in  vitro generated Tc1 and Tc17 cells 
(0.5 ×  106 cells/well) were measured in non-buffered DMEM 
without phenol red (containing 25  mM glucose, 2  mM l- 
glutamine, and 1 mM sodium pyruvate) under basal conditions 
and in response to 1  µM oligomycin, 0.5  µM fluoro-carbonyl 
cyanide phenylhydrazone, and 1 µM rotenone + 1 µM antimycin 
A (Sigma). The cells were analyzed with the XFe-96 Extracellular 
Flux Analyzer (Seahorse Bioscience).
FigUre 1 | Tc17 cells persist and expand rapidly following a challenge in vivo. Tc1 cells (CD45.2+) and Tc17 cells (CD45.1+/CD45.2+) were generated in vitro from 
OT-I mice. The cells were co-injected (2 × 106 total cells) into CD45.1+ recipient mice. The mice were immunized i.p. with OVA protein + CFA at day 23 following 
adoptive transfer of Tc1 and Tc17 cells. (a) Left, dot plot depicting the input and the frequencies of Tc1 and Tc17 cells in blood at days 10, 20, and 27 after adoptive 
transfer. Right, number of transferred Tc1 (white circles) and Tc17 cells (black circles) per microliter of blood at days 10, 20, and 27. Two-tailed Mann–Whitney test 
*p < 0.05, **p < 0.01, n = 4–5. (B) Dot plots depicting transferred Tc1 and Tc17 cells in peritoneal cavity, spleen, peripheral lymph nodes (PLN), mesenteric lymph 
node (MLN), and parathymic lymph nodes (pTLN) at day 27 after adoptive transfer. (c) Number of transferred Tc1 (white bars) and Tc17 cells (black bars) at day 27 
in peritoneal cavity, spleen, PLN, MLN, and pTLN. Two-tailed Mann–Whitney test **p < 0.01, n = 6. (D) Cytokine production following PMA plus ionomycin 
stimulation was analyzed on transferred Tc17 cells (CD45.1+/CD45.2+ cells) obtained from spleen and peritoneal cavity of recipient mice. Two-tailed Mann–Whitney 
test **p < 0.01, n = 6.
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statistical analysis
Data are presented as mean ±  SEM. Differences between two 
groups were determined using two-tailed Mann–Whitney test. 
Differences between more than two groups were determined 
using one-way ANOVA with Tukey or Bonferroni post-test. 
A two-way ANOVA with Bonferroni post-test was used to compare 
secondary expansion rates. Statistical analysis and graphs were 
obtained with GRAPHPAD PRISM (GraphPad Software Inc).
resUlTs
Tc17 cells expand rapidly following  
a secondary challenge
In a previous study, we have demonstrated that Tc17 cells are 
endowed with high antitumor capacity and persistence, despite 
displaying a reduced cytotoxic potential in vitro (12). These obser-
vations lead us to hypothesize that Tc17 cells present a memory 
phenotype. To test this hypothesis, we co-transferred in  vitro-
generated Tc1 and Tc17 cells obtained from OT-I mice into wild 
type mice and then 3 weeks later, the mice were immunized i.p. 
with OVA-CFA. We analyzed the persistence and expansion of 
Tc1 and Tc17 cells before and after OVA immunization. As shown 
in Figure 1A, 10 and 20 days after the co-transfer, we could only 
detect the presence of Tc17 cells in blood, and these cells suffered a 
two-fold expansion following immunization with OVA, whereas 
Tc1 cells remained undetected. Accordingly, Tc17 cells were 
mainly found in the peritoneal cavity while Tc1 cells were present 
in low frequencies, ruling out the possibility that Tc1 cells were 
absent in blood because they were more efficiently recruited to 
the peritoneal cavity (Figures 1B,C). Interestingly, besides being 
detected in the peritoneal cavity, Tc17 cells were also present in 
spleen and secondary lymph nodes such as peripheral lymph 
nodes (PLN), mesenteric lymph node (MLN), and parathymic 
lymph nodes (pTLN) (Figures 1B,C). This observation suggests 
that Tc17 cells may be recruited to effector tissues but also, that 
a portion of Tc17 cells may remain circulating within second-
ary lymph nodes as a reservoir for future encounter with their 
cognate antigen. Next, we tested whether Tc17 cells continued 
to produce IL-17 or could give rise to IFN-γ-producing cells. As 
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shown in Figure 1D, a high percentage of transferred Tc17 cells 
differentiated into IFN-γ-producing cells in spleen and peritoneal 
cavity, whereas a small fraction of Tc17 cells continued to produce 
IL-17 in spleen, confirming their high plasticity in this setting. 
Tc17 cells also expanded more rapidly and outnumbered Tc1 cells 
following in vitro polyclonal activation with anti-CD3 and anti-
CD28 antibodies (data not shown). Taken together, these results 
demonstrate the ability of Tc17 cells to persist in the long term 
and rapidly expand upon a challenge.
Next, we evaluated whether Tc17 cells could differentiate to 
memory cells in vivo which could expand rapidly following a re-
challenge with their cognate antigen. For this, we co-transferred 
in vitro-generated Tc1 and Tc17 cells obtained from OT-I mice 
into wild-type mice, and 24 h later, the mice were challenged with 
OVA. Four weeks later, mice were re-challenged with OVA and 
the frequencies of transferred cells in blood, PLN and spleen were 
analyzed. In this setting, the composition of Tc1 and Tc17 cells 
remained similar to the input before the re-challenge with OVA 
(dotted line, Figure S1C in Supplementary Material). However, 
following re-challenge with OVA protein (day 34), we found that 
Tc17 cells rapidly expanded (Figures S1A,B in Supplementary 
Material) and became almost 90% of transferred cells (Figure 
S1C in Supplementary Material), confirming that Tc17 cells 
are superior than Tc1 cells in proliferating in response to their 
cognate antigen. Similar results were obtained when analyzing 
the composition of transferred cells in spleen and PLN (Figure 
S1C in Supplementary Material). Interestingly, 1 week after the 
re-challenge, Tc17 cells found in the spleen and PLN gave rise to 
IFN-γ-producing cells (54.6 ± 7.3%) that do not express KLRG1 
but express high levels of CD44 and CD127 (Figure S1D in 
Supplementary Material). Moreover, we found that a proportion 
of these Tc17 cells (29.6 ± 3.7%) express CD62L, which explains 
their potential to migrate within secondary lymph nodes (Figure 
S1D in Supplementary Material).
Tc17 cells Present a Migration Pattern of 
central Memory T cells
In agreement with our previous observations in tumor bearing 
mice (12), we demonstrated that transferred Tc17 cells were always 
found in the spleen and secondary lymphoid organs (Figure 1B; 
Figure S1C in Supplementary Material), suggesting that they have 
a circulation pattern similar to central memory (TCM) cells. To 
study the migration pattern of Tc17 cells, in vitro-generated Tc17 
and Tc1 cells were stained and transferred into congenic mice. 
24 h later, we analyzed spleen, PLN, MLN, bone marrow, liver, 
lung, and blood for the presence of the transferred cells. As shown 
in Figure  2A, Tc17 cells migrated preferentially to secondary 
lymphoid organs such as the spleen, PLN, and MLN compared 
to Tc1 cells. In contrast, Tc1 cells preferentially migrated to the 
bone-marrow compared to Tc17 cells (Figure 2A).
Next, we tested whether Tc17 cells injected in peripheral tissues 
can become established as memory cells in secondary lymphoid 
organs. For this, we intradermally co-transferred Tc1 and Tc17 
cells in a 1:1 ratio into CD45.1+ mice and 30 days later, the pres-
ence of memory cells was analyzed in skin, spleen, PLN, MLN, 
bone marrow, liver, lung, and blood. As shown in Figure 2B, we 
did not find Tc1 or Tc17 cells in the skin, however, Tc17 cells were 
found in blood and in all the organs analyzed. Interestingly, when 
analyzing the absolute numbers, we observed that Tc17 cells were 
preferentially found in secondary lymphoid organs (Figure 2B). 
These results demonstrate that Tc17 cells are not retained in the 
skin but migrate into secondary lymphoid organs.
Tc17 cells Proliferate More robustly than 
Tc1 cells in response to homeostatic 
stimuli
To analyze the homeostatic response of Tc17 cells, we cultured 
Tc17 and Tc1 cells with the homeostatic cytokines IL-15 and IL-7, 
and the proliferation and absolute numbers of cells were analyzed 
3  days later. As shown in Figure  3A, Tc17 cells responded to 
both homeostatic cytokines while Tc1 cells proliferated only in 
response to IL-15, which is in agreement with the fact that only 
Tc17 cells express CD127. In spite of their rapid proliferation, 
Tc17 cells retained the ability to produce IL-17 and only a small 
fraction of cells produced IFN-γ (data not shown).
To further analyze the in  vivo homeostatic proliferation of 
Tc17 cells, Tc1 and Tc17 cells were transferred into Rag1−/− mice 
at a 1:1 ratio and several days later, the absolute number of 
transferred cells was analyzed. As shown in Figures 3B–D, both 
Tc1 and Tc17 cells were present in Rag1−/− mice 11 and 25 days 
following the transfer, but the absolute number of Tc17 cells in 
blood always doubled the absolute number of Tc1 cells. Moreover, 
a higher percentage of Tc17 cells were positive for Ki67 staining 
at day 25 compared to Tc1 cells (Figure 3E). Thus, Tc17 cells are 
much more responsive to homeostatic stimulation than Tc1 cells.
Tc17 cells Present a Transcriptional and 
Metabolic Profile of Memory T cells
We have previously shown that Tc17 cells express higher levels 
of tcf-7 and lef1 and lower levels of GzmB compared to Tc1 cells 
(12). To further characterize the phenotype of Tc17 cells, in vitro-
generated Tc1 and Tc17 cells were analyzed by real-time PCR and 
by FACS in search of additional markers related to memory cells 
and effector cells. As shown in Figure 4A, we observed that Tc17 
cells express markers related to memory T cells such as bcl-6 and 
lack markers of terminal differentiation such as tbx-21, eomes, 
and prdm1. On the other hand, Tc1 and Tc17 cells did not express 
Klf-2 transcriptional factor, which commands CD62L expression. 
Interestingly, in contrast to Tc1 cells, Tc17 cells present low levels 
of CD25, granzyme B, and TNF-α, while they express RORγt and 
produce high levels of IL-2 (Figure 4B).
Since Tc17 cells express high levels of bcl-6 and low levels of prdm1 
which suggests that Tc17 cells present a metabolic signature related to 
memory T cells, we sought to determine the metabolic profile of Tc17 
cells. A distinctive characteristic of memory CD8+ T cells is that they 
rely on an oxidative metabolism and present a high SRC (19). Thus, 
we determined the OCR and ECAR of in vitro-generated Tc1 and 
Tc17 cells and found that Tc17 cells present a higher OCR and SRC 
than Tc1 cells (Figures 5A,B). Moreover, Tc17 cells exhibit higher 
levels of complex IV proteins compared to Tc1 cells (Figures 5C,D 
and Figure S2 in Supplementary Material), suggesting that they pre-
sent an increased efficiency in respiration. All these data demonstrate 
FigUre 2 | Tc17 cells recirculate within secondary lymph nodes. (a) Tc1 and Tc17 lymphocytes were generated in vitro from CD45.2+ mice and stained with eFluor 
680 (5 µM) and CMTMR (10 µM) respectively. Then the cells were co-transferred (0.5 × 106 cells of each type) in CD45.1+ mice. Cell migration was evaluated 24 h 
later in several lymphoid and effector tissues. Homing index in each organ was calculated as (Tc17organ/Tc1organ)/(Tc17input/Tc1input), n = 3. (B) Tc1 cells (CD45.2+) and 
Tc17 cells (CD45.1+/CD45.2+) were generated in vitro and injected intradermally into congenic mice (CD45.1+). 32 days later, the number of transferred cells was 
analyzed in skin, spleen, peripheral lymph nodes (PLN), mesenteric lymph node (MLN), bone marrow, lung, liver, and blood of recipient mice, n = 3.
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that Tc17 cells rely mainly on an oxidative metabolism which has 
been already related to a memory CD8+ T cell phenotype.
DiscUssiOn
Two main features characterize memory T  cells; first, they are 
long-lived and maintained independently of stimulation, and sec-
ond, they are functionally improved and respond more quickly 
and efficiently to repeated encounters with a specific pathogen 
than naive T  cells. Also, depending on their migratory prefer-
ences, they can be classified into at least three subtypes: central 
memory T cells (TCM), effector memory T cells (TEM), and tissue-
resident memory T cells (TRM) (20–22). Although the potential of 
naive CD8+ T cells to generate memory cells has been extensively 
studied, the potential of different CD8+ T  cell effector subsets, 
especially Tc17 cells, to persist and become memory cells has not 
been fully characterized. Here, we show that Tc17 cells present 
functional features of TCM cells such as the long-term maintenance, 
secondary expansion capacity, an oxidative metabolic profile, and 
a preferential trafficking within peripheral lymphoid tissues.
An essential property required for an efficient recall response 
is the ability of memory T  cells to proliferate in response to 
antigenic stimulation (secondary expansion). In this work, we 
observed that unlike Tc1 cells, Tc17 lymphocytes were able to 
rapidly expand in vivo after secondary exposure to the antigen. 
This quality has been linked to the production and autocrine 
FigUre 3 | Tc17 cells proliferate in response to homeostatic stimuli. (a) In vitro-generated Tc1 and Tc17 cells were cultured in the presence of IL-15 (25 ng/ml) or 
IL-7 (10 ng/ml). 3 days later, cells were harvested and analyzed by FACS for Ki-67 staining. Graph on the right shows the number of cells per milliliter obtained 
following 3 days of culture. The dotted line represents the number of cells cultured at day 0. One-way ANOVA and Bonferroni post-test (control versus treated), 
*p < 0.05, ****p < 0.0001, n = 3. (B–e) Tc1 and Tc17 lymphocytes were generated in vitro from CD45.2+ and CD45.1+/CD45.2+ mice, respectively, and co-
transferred (0.5 × 106 cells of each type) into Rag1−/− mice. (B) Dot plots show the percentage of transferred Tc1 and Tc17 cells in blood at different time points.  
(c) Composition of transferred Tc1 and Tc17 cells in blood at different time points. Dotted line represents the input. (D) Number of transferred Tc1 and Tc17 cells  
per microliter of blood. (e) Percentage of Ki-67+ cells within Tc1 and Tc17 cells in blood. Pooled data from two independent experiments (n = 9–10). Two-tailed 
Mann–Whitney test *p < 0.05, **p < 0.01, ****p < 0.0001.
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signaling of IL-2 (23), and consequently, it has been reported that 
T cells with a lower degree of differentiation such as TCM produce 
higher levels of IL-2 in comparison to more differentiated T cells 
as TEM (20, 24, 25). Moreover, it has been suggested that IL-2 pro-
duction by TCM cells is important in their enhanced proliferative 
capacity (26). Consistently, we observed that a high percentage 
of Tc17 lymphocytes generated in vitro produce IL-2, and even a 
fraction of the secondary progeny of Tc17 lymphocytes continues 
to produce IL-2 in vivo (12).
Recent studies have shown that CD25 (IL-2 receptor alpha 
chain) expression may determine the fate between memory 
versus effector cells (27, 28). It has been suggested that during 
the asymmetric distribution of CD25 during the first cell divi-
sion of naive T cells, the population of CD25 low cells give rise 
FigUre 4 | Tc17 cells present a memory-like phenotype. (a) The expression of memory and effector CD8+ T cell markers was analyzed by real-time PCR from 
cell-sorted naive CD8+ T cells and in vitro-generated Tc1 and Tc17 cells. The mRNA level was calculated relative to the expression of the housekeeping gene HPRT 
and normalized by the expression of naive T cells. One-way ANOVA and Tukey post-test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 3–4.  
(B) Expression of IL-17A, interferon (IFN)-γ, CD25, GzmB, IL-2, TNF-α, T-bet, and Rorγt by in vitro-generated Tc1 and Tc17 cells measured by FACS.  
Two-tailed Mann–Whitney test *p < 0.05, **p < 0.01, ****p < 0.0001, n = 3–7.
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FigUre 5 | Tc17 cells present a metabolic profile of memory T cells. (a,B) Oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) from 
in vitro-generated Tc1 and Tc17 cells were measured under basal conditions and in response to 1 µM oligomycin, 0.5 µM fluoro-carbonyl cyanide 
phenylhydrazone, and 1 µM rotenone+ 1 µM antimycin A. Representative of two independent experiments. Two-tailed Mann–Whitney test, **p < 0.01, n = 6–7. 
(c) ETC Complex I, II, III, IV, and V proteins were analyzed by western blot in Tc17 and Tc1 cells. Representative of three independent experiments.  
(D) Quantification of ETC complexes, n = 3.
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to memory T lymphocytes (28). We have shown that Tc17 cells 
express low levels of CD25, which is consistent with the pheno-
type of memory precursors as previously reported by Arsenio and 
collaborators.
The ability of memory T lymphocytes to persist in vivo depends 
primarily on exposure to cytokines such as IL-7 and IL-15 (29), 
which promote cell survival by inducing the expression of anti-
apoptotic proteins such as Bcl-2 (30). In this work we observed 
that Tc17 lymphocytes show a high expression of the IL-7 receptor 
alpha chain (CD127) in vivo, similar to that reported in the litera-
ture (11), suggesting that Tc17 lymphocytes may have advantages 
in long-term survival. In agreement with this idea, we observed 
that Tc17 lymphocytes expand more rapidly than Tc1 cells in vitro 
when cultured in the presence of IL-7 and also when transferred 
into Rag1-deficient mice. In support of this idea, the group of 
Klein has recently reported that vaccine-induced memory Tc17 
cells express CD127, are durable and stable, and can persist for a 
year as functional IL-17A+ memory cells (31).
Interestingly, only Tc17 lymphocytes were found in lymphoid 
organs (spleen and lymph nodes) of mice after antigenic stimula-
tion. This pattern of migration through the lymphoid organs is 
a hallmark of central memory T  lymphocytes and depends on 
L-selectin (CD62L) and the chemokine receptor CCR7 expres-
sion (20, 21). Paradoxically, we observed that Tc17 lymphocytes 
generated in vitro do not express CD62L at the time of adoptive 
transfer (data not shown), nor the Klf-2 transcriptional factor, 
which commands CD62L expression. However, a fraction of the 
Tc17 lymphocytes (almost 30%) can re-express CD62L in  vivo 
and maintain its expression even after secondary antigenic stimu-
lation. In agreement, evidence from Arsenio and collaborators 
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has shown that following antigenic stimulation, CD62L is initially 
down regulated and in time, it is subsequently upregulated in a 
population of memory T cells (28). This property of migrating 
through the lymphoid organs could allow the contact of the Tc17 
lymphocytes with antigen-presenting cells and in this way favor 
the secondary response. In this line, previous studies have posi-
tively related the ability of the T lymphocytes to migrate to the 
lymph nodes with greater effectiveness in schemes of antitumor 
cellular immunotherapy (24, 32).
Evidence from the literature suggests that the Wnt-β-catenin 
pathway promotes the acquisition of the memory T  cell phe-
notype while restricting the differentiation of CD8+ T lympho-
cytes into terminal effector T cells (32–34). Interestingly, in this 
work, we observed that Tc17 lymphocytes generated in  vitro 
show a high expression of the transducers of the Wnt-β-catenin 
pathway, namely Tcf-7 and Lef-1, similar to the phenotype 
already reported in memory CD8+ T  lymphocytes (32). This 
is especially relevant since studies conducted by the Restifo 
group have shown that the pharmacological activation of the 
Wnt pathway is sufficient to restrict terminal differentiation in 
CD8+ T lymphocytes, favoring the generation of highly undif-
ferentiated memory T  lymphocytes with a potent therapeutic 
potential (32, 35).
Bcl-6 is another important factor in maintaining the memory 
phenotype and has been reported to accumulate as CD8+ T lym-
phocytes transit from the effector into the memory phenotype 
(36). In agreement, overexpression of Bcl-6 in CD8+ T lympho-
cytes has shown to promote the generation of TCM lymphocytes 
in vivo (37). The fact that Tc17 lymphocytes express higher levels 
of Bcl-6, Tcf-7, and Lef-1 could be a consequence of stimulation 
of the IL-6/STAT-3 pathway. Indeed, several cytokines related 
to the Tc17 program such as IL-6, IL-21, and IL-23 stimulate 
STAT-3 phosphorylation, which induces the expression of 
RORγt and IL-17, and represses the expression of granzyme B 
and IFN-γ (13, 14). Moreover, it has been reported that STAT-3 
controls the expression of Bcl-6 (36) and Tcf-7 (38) in CD8+ and 
CD4+ T  lymphocytes, respectively. In fact, STAT3-deficient CD8+ 
T lymphocytes are short-lived, fail to generate TCM lymphocytes 
in vivo, and have a lower Bcl-6 expression compared to normal 
cells (36). Moreover, recent evidence from the group of Bosselut 
(39) has clearly demonstrated that STAT3 inhibits cytotoxic effec-
tor molecules such as granzymes and cytotoxic regulators such 
as T-bet and Eomes. Thus, signaling through the IL-6/STAT-3 
pathway could contribute to the acquisition of the memory 
program observed in Tc17 lymphocytes.
Besides being involved in inhibiting Blimp-1 expression 
(40), Bcl-6 participates in the repression of genes that are 
critical to the glycolysis pathway, favoring the catalytic pathway 
(41). Memory CD8+ T cells are characterized by being highly 
dependent on a mitochondrial metabolism (19, 42), and the 
inhibition of glycolysis has been shown to improve the genera-
tion of memory T cells (43). It has been shown that memory 
CD8+ T cells present a high SRC, high OCRs, and mitochondrial 
mass compared to naive T cells, which allows explaining their 
long term survival and function (19, 42). The SRC constitutes 
the extra mitochondrial capacity available under stress condi-
tions and increased work. In this line, our results demonstrate 
that Tc17 cells present higher OCR and SRC compared to Tc1 
cells, thus suggesting that they exhibit a metabolic signature 
related to memory CD8+ T cells.
The results presented here demonstrate that following adop-
tive transfer, IL-17 production by Tc17 cells is lost when these 
cells enter effector tissues such as the peritoneal cavity; however, 
we detected a small fraction of Tc17 cells that still produce IL-17 
in the spleen. Some reports from the literature demonstrate that 
IL-17 production by Tc17 and Th17 cells favors the recruitment 
of neutrophils into different tissues such as the lung in a murine 
model of lethal influenza infection (44), the tumor in a model 
of murine melanoma (10) and tumor draining lymph nodes 
in a murine colon carcinoma model (45). In all these reports, 
neutrophils have demonstrated to be pivotal in the induction of 
a protective immunity, thus IL-17 production by Tc17 cells in 
lymph nodes may be part of the effector mechanisms used by 
Tc17 cells to promote effective immune responses. Further stud-
ies are needed in order to demonstrate a role of IL-17 production 
by Tc17 cells in the recruitment of neutrophils to secondary 
lymph nodes.
Both phenotypic and functional properties observed in 
Tc17 lymphocytes (persistence, secondary expansion, lymph 
node migration, and self-renewal) strongly suggest that Tc17 
lymphocytes possess qualities suitable for use in antitumor adop-
tive therapies. In agreement with this idea, our group together 
with other authors has shown that the adoptive therapy with 
Tc17 lymphocytes generated in  vitro promotes the elimination 
of established melanoma tumors in mice (9, 10, 12) through 
an IFN-γ-dependent mechanism (10). Interestingly, following 
adoptive transfer, Tc17 cells gain the ability to produce IFN-γ. 
In light of these results, we can conclude that the role of Tc17 
cells in this context may be to serve as a self-renewing reservoir 
of cells that will continuously give rise to Tc1-like cells. In spite of 
this, the therapeutic effectiveness of Tc17 lymphocytes has been 
questioned by studies showing that Tc1 lymphocytes are more 
efficient than Tc17 lymphocytes in the eradication of established 
tumors based on the number of transferred cells (10, 12). It is 
possible to reconcile these results by arguing that the high effector 
capacity of Tc1 lymphocytes is crucial to mediate a rapid elimina-
tion of tumor cells in a first stage, whereas the memory qualities 
of Tc17 lymphocytes would support a continuous attack in time, 
conferring immunity for longer periods.
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